Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
SSR240600C Treatment in Women With Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00564226
- Locations
- 🇺🇸
Sanofi-Aventis Aministrative Office, Bridgewater, New Jersey, United States
🇵🇹Sanofi-Aventis Administrative Office, Porto Salvo, Portugal
Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2007-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT00564187
- Locations
- 🇹🇳
Sanofi-Aventis, Megrine, Tunisia
A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2009-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00563914
- Locations
- 🇰🇪
Sanofi-Aventis Administrative Office, Nairobi, Kenya
Leflunomide + Methotrexate in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT00563849
- Locations
- 🇰🇷
Sanofi-Aventis, Pusan, Korea, Republic of
20 Week Bridging Study in Type II DM
- Conditions
- Diabetes Mellitus Type II
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2007-11-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT00563225
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
- Conditions
- Hyperuricemia
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT00563771
- Locations
- 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of
The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1005
- Registration Number
- NCT00562809
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 75
- Registration Number
- NCT00562172
- Locations
- 🇰🇷
Sanofi-aventis, Seoul, Korea, Republic of
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
- Conditions
- Colorectal NeoplasmsNeoplasm Metastasis
- Interventions
- Drug: PlaceboDrug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1226
- Registration Number
- NCT00561470
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840076, Fountain Valley, California, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840071, Stamford, Connecticut, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840096, Paducah, Kentucky, United States
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2007-11-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 241
- Registration Number
- NCT00561964